GLP-1 Weight Loss Drug Under Development
Recent research has revealed unexpected side effects linked to GLP-1 agonists like Ozempic, Wegovy, Mounjaro, and Zepbound. These drugs, commonly prescribed for diabetes and obesity, may disrupt medical imaging procedures, including PET and CT scans.
The Cleveland Clinic points out that CT scans are essential for providing detailed images to identify lesions, tumors, and other irregularities, while PET scans help assess organs and tissues for cancer activity.
A case study shared during the 38th Annual Meeting of the European Society of Nuclear Medicine in Barcelona discussed findings from cancer scans of patients using GLP-1 medications, revealing some unusual scan results that might be confused with signs of disease.
According to Dr. Peter Strawhall, the lead author of the study and a medical director at Alliance Medical in the UK, the team noticed that one patient had an unexpected uptake of a GLP-1 agonist, prompting a more extensive review across the network. “These altered patterns are appearing more frequently, yet there’s currently no national or international guidance in the UK to tackle this new issue,” he mentioned.
Misinterpretations of scan results can potentially lead to unnecessary tests, incorrect cancer evaluations, and delayed treatments, which understandably can create anxiety for patients. Dr. Strawhall emphasized that understanding how GLP-1 drugs influence imaging could help physicians avoid confusion and ensure timely, accurate care.
Despite these findings, the researchers do not recommend patients halt their GLP-1 medication before scans. They highlight the importance of considering a patient’s medication history while interpreting imaging results. The team aims to gather more data from imaging centers around the globe to bolster their findings.
Dr. Sue DeCotis, a weight loss physician in New York City, has noted that these results are still quite preliminary. “They noted an increase but didn’t specify which organs or body parts were affected,” she said.
Moving forward, further data collection will be crucial to fully understand these observations. Dr. Adam Wolfberg, chief medical officer of Virta Health in Massachusetts, added that GLP-1 impacts glucose metabolism and could affect the uptake of tracers used in PET scans. He emphasized that context is essential for accurate image interpretation.
Wolfberg remarked, however, that he doesn’t view this discovery as particularly alarming, stating that skilled oncologists and radiologists always consider a patient’s overall medical situation when assessing imaging studies. He echoed the sentiment that more comprehensive data is necessary before any changes to medical practices can be recommended.
Researchers and manufacturers of GLP-1 drugs have been contacted for further comment.
